Rocket reports Danon safety clearance and $180M PRV sale in Q2 2026 update
All three initial Danon disease patients cleared safety observation under Rocket's modified Phase 2 protocol, as the company sits on $283.7 million in cash after monetizing its priority review voucher.
Rocket Pharmaceuticals said on August 10, 2026 that all three patients dosed under the modified pivotal Phase 2 protocol for RP-A501 in Danon disease completed the protocol-defined safety observation period, with no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns observed at the recalibrated dose and refined immunomodulatory regimen.1 The company chose the recalibrated Phase 2 dose of 3.8 × 10¹³ GC/kg based on the current drug product's characteristics, the underlying biology of Danon disease, and prior Phase 1 experience.1
Rocket said it is in discussions with the FDA on dosing additional patients and finishing the pivotal trial, and plans to give an update on the regulatory path in the second half of 2026.1 The company also plans an investor webinar in the second half of 2026 covering the broader Danon program, and its global natural history study has enrolled more than 50 patients, including both males and females.1
For RP-A601 in PKP2-ACM, Rocket said a regulatory update on a potential pivotal study design is expected in the second half of 2026, and that the ongoing Phase 1 study remains open and actively enrolling to further characterize biological activity across a broader range of disease severity.1 For RP-A701 in BAG3-DCM, patient screening and enrollment has begun, with initial patient dosing anticipated in the second half of 2026.1
On the commercial side, Rocket said it anticipates commercial availability and the start of patient onboarding for KRESLADI in the fourth quarter of 2026.1 The company closed the sale of its Rare Pediatric Disease Priority Review Voucher on June 12, 2026 for gross proceeds of $180 million, which it said strengthened its financial position and supports its cardiovascular pipeline.1
Rocket reported cash, cash equivalents and investments of $283.7 million as of June 30, 2026,1 and said this is expected to fund operations into the second quarter of 2028.1 The company also reported net income of $123.2 million, or $1.09 per basic share, for the quarter, compared to a net loss of $68.9 million a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.